• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.(V600E)BRAF与RAF-MEK信号通路的反馈抑制功能障碍以及该通路转录输出的增加有关。
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24. doi: 10.1073/pnas.0900780106. Epub 2009 Feb 27.
2
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.RAF 抑制剂 PLX4032 以 V600E BRAF 选择性方式抑制 ERK 信号和肿瘤细胞增殖。
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.
3
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.BRAF V600E突变破坏了AZD6244诱导的细胞外信号调节激酶与Raf蛋白之间负反馈通路的消除。
Cancer Res. 2008 Aug 1;68(15):6145-53. doi: 10.1158/0008-5472.CAN-08-1430.
4
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.BRAF V600E 和非 V600E 突变型肺癌中 MAPK 信号转导的受体酪氨酸激酶调控的独特依赖性。
Oncogene. 2018 Mar;37(13):1775-1787. doi: 10.1038/s41388-017-0035-9. Epub 2018 Jan 19.
5
Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.由涉及MEK-ERK途径而非FBXW7肿瘤抑制因子的负反馈回路对BRAF蛋白稳定性进行调控。
Cell Signal. 2016 Jun;28(6):561-71. doi: 10.1016/j.cellsig.2016.02.009. Epub 2016 Feb 17.
6
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.RAF 抑制剂可使野生型 BRAF 细胞中的 RAF 二聚体和 ERK 信号转导激活。
Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.
7
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.鉴定黑素瘤中 (V600E)BRAF/MEK 信号的直接转录靶标。
Pigment Cell Melanoma Res. 2009 Dec;22(6):785-98. doi: 10.1111/j.1755-148X.2009.00618.x. Epub 2009 Aug 4.
8
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.BRAF(V600E)抑制剂PLX4032可增加黑色素瘤细胞中I型胶原蛋白的合成。
Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.
9
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.中间活性(L597V)BRAF 突变体通过增强 RAF/MEK/ERK 通路的信号转导,作为致癌 RAS 的上位修饰因子而起作用。
Genes Dev. 2012 Sep 1;26(17):1945-58. doi: 10.1101/gad.193458.112. Epub 2012 Aug 14.
10
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Raf激酶活性抑制剂在体外和体内均可阻断具有RET/PTC或BRAF突变的甲状腺癌细胞的生长。
Clin Cancer Res. 2006 Mar 15;12(6):1785-93. doi: 10.1158/1078-0432.CCR-05-1729.

引用本文的文献

1
Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?靶向细胞外信号调节激酶的双特异性蛋白磷酸酶:癌症生物学中的朋友还是敌人?
Int J Mol Sci. 2025 Aug 28;26(17):8342. doi: 10.3390/ijms26178342.
2
Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma.SHP2的联合抑制克服了BRAF V600E驱动的高级别胶质瘤对1型BRAF抑制剂的适应性耐药。
Neurooncol Adv. 2025 Aug 2;7(1):vdaf170. doi: 10.1093/noajnl/vdaf170. eCollection 2025 Jan-Dec.
3
Discovery of KRAS(G12D) selective degrader ASP3082.KRAS(G12D)选择性降解剂ASP3082的发现。
Commun Chem. 2025 Aug 23;8(1):254. doi: 10.1038/s42004-025-01662-4.
4
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.通过靶向耐药细胞的选择性优势来延长肺癌对表皮生长因子受体(EGFR)抑制的反应。
Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w.
5
MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions.胶质母细胞瘤中的MEK抑制:当前观点与未来方向
Int J Mol Sci. 2025 Jul 17;26(14):6875. doi: 10.3390/ijms26146875.
6
COP1 Deficiency in BRAF Melanomas Confers Resistance to Inhibitors of the MAPK Pathway.BRAF 黑色素瘤中 COP1 缺陷赋予对 MAPK 通路抑制剂的抗性。
Cells. 2025 Jun 25;14(13):975. doi: 10.3390/cells14130975.
7
Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity.Cx43通过降低DNA修复能力增强对BRAF/MEK抑制剂的反应。
Nat Commun. 2025 Jul 4;16(1):6168. doi: 10.1038/s41467-025-60971-3.
8
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.阿特珠单抗联合考比替尼或艾达司他丁治疗转移性雌激素受体阳性乳腺癌的Ib/II期试验。
NPJ Breast Cancer. 2025 Jun 21;11(1):61. doi: 10.1038/s41523-025-00773-4.
9
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF-mutant glioma.BRAF/MEK抑制可诱导细胞状态转变,增强BRAF突变型胶质瘤对免疫检查点的敏感性。
Cell Rep Med. 2025 Jun 17;6(6):102183. doi: 10.1016/j.xcrm.2025.102183. Epub 2025 Jun 12.
10
Epigenomic profiling of papillary thyroid carcinoma reveals distinct subtypes with clinical implications.甲状腺乳头状癌的表观基因组分析揭示了具有临床意义的不同亚型。
NPJ Precis Oncol. 2025 May 10;9(1):136. doi: 10.1038/s41698-025-00932-7.

本文引用的文献

1
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.口服小分子促分裂原活化蛋白激酶激酶1/2抑制剂AZD6244(ARRY-142886)在晚期癌症患者中的I期药代动力学和药效学研究。
J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7.
2
Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.Sprouty2在非小细胞肺癌中的下调通过细胞外信号调节激酶途径依赖性和非依赖性机制促进肿瘤恶性进展。
Mol Cancer Res. 2007 May;5(5):509-20. doi: 10.1158/1541-7786.MCR-06-0273.
3
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.双特异性蛋白磷酸酶对丝裂原活化蛋白激酶信号传导的差异调节。
Oncogene. 2007 May 14;26(22):3203-13. doi: 10.1038/sj.onc.1210412.
4
A module of negative feedback regulators defines growth factor signaling.一个负反馈调节因子模块定义了生长因子信号传导。
Nat Genet. 2007 Apr;39(4):503-12. doi: 10.1038/ng1987. Epub 2007 Feb 25.
5
PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways.PANTHER版本6:具有生物途径扩展表示的蛋白质序列和功能进化数据。
Nucleic Acids Res. 2007 Jan;35(Database issue):D247-52. doi: 10.1093/nar/gkl869. Epub 2006 Nov 27.
6
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.连通性图谱:利用基因表达特征连接小分子、基因与疾病。
Science. 2006 Sep 29;313(5795):1929-35. doi: 10.1126/science.1132939.
7
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.由无BRAF特征的特定基因表达谱定义的黑色素瘤转移潜能
Pigment Cell Res. 2006 Aug;19(4):290-302. doi: 10.1111/j.1600-0749.2006.00322.x.
8
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition.Akt1和Akt2在调节细胞迁移和上皮-间质转化中的不同作用。
J Cell Biol. 2005 Dec 19;171(6):1023-34. doi: 10.1083/jcb.200505087.
9
BRAF mutation predicts sensitivity to MEK inhibition.BRAF突变预示着对MEK抑制的敏感性。
Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6.
10
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology.生物调节网络的分子相互作用图谱:系统生物学的通用准则
Mol Biol Cell. 2006 Jan;17(1):1-13. doi: 10.1091/mbc.e05-09-0824. Epub 2005 Nov 2.

(V600E)BRAF与RAF-MEK信号通路的反馈抑制功能障碍以及该通路转录输出的增加有关。

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

作者信息

Pratilas Christine A, Taylor Barry S, Ye Qing, Viale Agnes, Sander Chris, Solit David B, Rosen Neal

机构信息

Department of Pediatrics, Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24. doi: 10.1073/pnas.0900780106. Epub 2009 Feb 27.

DOI:10.1073/pnas.0900780106
PMID:19251651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2649208/
Abstract

Tumors with mutant BRAF and those with receptor tyrosine kinase (RTK) activation have similar levels of phosphorylated ERK, but only the former depend on ERK signaling for proliferation. The mitogen-activated protein kinase, extracellular signal-regulated kinase kinase (MEK)/ERK-dependent transcriptional output was defined as the genes whose expression changes significantly 8 h after MEK inhibition. In (V600E)BRAF cells, this output is comprised of 52 genes, including transcription factors that regulate transformation and members of the dual specificity phosphatase and Sprouty gene families, feedback inhibitors of ERK signaling. No such genes were identified in RTK tumor cells, suggesting that ERK pathway signaling output is selectively activated in BRAF mutant tumors. We find that RAF signaling is feedback down-regulated in RTK cells, but is insensitive to this feedback in BRAF mutant tumors. Physiologic feedback inhibition of RAF/MEK signaling down-regulates ERK output in RTK cells; evasion of this feedback in mutant BRAF cells is associated with increased transcriptional output and MEK/ERK-dependent transformation.

摘要

具有BRAF突变的肿瘤和那些具有受体酪氨酸激酶(RTK)激活的肿瘤具有相似水平的磷酸化ERK,但只有前者的增殖依赖于ERK信号传导。丝裂原活化蛋白激酶、细胞外信号调节激酶激酶(MEK)/ERK依赖性转录输出被定义为在MEK抑制后8小时其表达发生显著变化的基因。在(V600E)BRAF细胞中,这种输出由52个基因组成,包括调节转化的转录因子以及双特异性磷酸酶和Sprouty基因家族的成员,它们是ERK信号传导的反馈抑制剂。在RTK肿瘤细胞中未鉴定出此类基因,这表明ERK途径信号传导输出在BRAF突变肿瘤中被选择性激活。我们发现RAF信号传导在RTK细胞中被反馈下调,但在BRAF突变肿瘤中对这种反馈不敏感。RAF/MEK信号传导的生理性反馈抑制会下调RTK细胞中的ERK输出;BRAF突变细胞中这种反馈的逃避与转录输出增加和MEK/ERK依赖性转化有关。